Page last updated: 2024-11-06

4-hydroxypropranolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-hydroxypropranolol: metabolite of propanolol; RN given refers to parent cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID91565
CHEMBL ID1137
CHEBI ID168939
MeSH IDM0041611

Synonyms (23)

Synonym
CHEBI:168939
4-[2-hydroxy-3-(propan-2-ylamino)propoxy]naphthalen-1-ol
10476-53-6
4'-hydroxypropanolol
4-hydroxypropranolol
CHEMBL1137
2449qp4svp ,
unii-2449qp4svp
1-(4-hydroxynaphth-1-yloxy)-3-isopropylamino-2-propanol
4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-1-naphthalenol
bdbm50405147
CWEPACWBWIOYID-UHFFFAOYSA-N
4-[2-hydroxy-3-(isopropylamino)propoxy]-1-naphthol #
(+/-)-4-hydroxypropranolol
1-naphthalenol, 4-(2-hydroxy-3-((1-methylethyl)amino)propoxy)-
recemic 4-hydroxypropranolol
(+/-)-4-hydroxypropranolol, hydrochloride
4-(2-hydroxy-3-(isopropylamino)propoxy)naphthalen-1-ol
69499-28-1
Q27253809
DTXSID70893062
4-{2-hydroxy-3-[(propan-2-yl)amino]propoxy}naphthalen-1-ol
PD044965

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The disposition of 4'-hydroxypropranolol (HOP) was determined after iv administration to dogs (2 mg/kg; N = 5) and the pharmacokinetic parameters were calculated from plasma measurements."( Pharmacokinetics and metabolism of the pharmacologically active 4'-hydroxylated metabolite of propranolol in the dog.
Christ, DD; Oatis, JE; Walle, T; Walle, UK,
)
0.13
" The pharmacokinetic data are consistent with a decrease in intrinsic hepatic clearance of propranolol, leading to an increase in bioavailability at steady-state."( Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.
Bottorff, MB; Lalonde, RL; Mirvis, DM; Pieper, JA; Straka, RJ, 1987
)
0.27
"We determined the haemodynamic, electrocardiographic and electrophysiologic effects, and the pharmacokinetic properties of 4'-hydroxypropranolol (4'-OHP) by conducting three different experiments in dogs."( Haemodynamic, electrocardiographic, electrophysiologic and pharmacokinetic activity of 4'-hydroxypropranolol in dogs.
Muir, WW; Sams, RA; Schall, SF, 1996
)
0.29

Bioavailability

ExcerptReferenceRelevance
" These results indicate that the poor absorption of P from the gastrointestinal tract might be one of the factors causing the low bioavailability of P observed after administration of the sustained-release formulation."( Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Kashiwada, K; Ogata, H; Ohira, M; Someya, K; Takahashi, H; Warabioka, R, 1990
)
0.28
"Mechanisms and variations in the food-induced increase in the bioavailability of propranolol were assessed by single-dose (80 mg) studies in healthy volunteers who took the drug on an empty stomach, immediately after a protein-rich breakfast, and together with a carbohydrate-rich, protein-poor breakfast."( Mechanisms and variations in the food effect on propranolol bioavailability.
Liedholm, H; Melander, A; Wåhlin-Boll, E, 1990
)
0.28
" The pharmacokinetic data are consistent with a decrease in intrinsic hepatic clearance of propranolol, leading to an increase in bioavailability at steady-state."( Propranolol pharmacokinetics and pharmacodynamics after single doses and at steady-state.
Bottorff, MB; Lalonde, RL; Mirvis, DM; Pieper, JA; Straka, RJ, 1987
)
0.27
" Area under the curve estimates suggested that the bioavailability of the slow-release formulation following single-dose administration was about one-third that of the conventional preparation."( Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration.
Drummer, OH; Louis, WJ; McNeil, J; Pritchard, E, 1981
)
0.49
" Previous evidence suggests that the dose-dependent bioavailability of racemic propranolol may be partly due to product inhibition."( (S)-4'-hydroxypropranolol causes product inhibition and dose-dependent bioavailability of propranolol enantiomers in the isolated perfused rat liver and in rat liver microsomes.
Ghabrial, H; Morgan, DJ; Nand, RA; Smallwood, RA, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
"The influence of sustained absorption on the oral availability of propranolol (P) and the metabolic disposition of P were investigated by obtaining the partial metabolic clearances (CLm) following long-acting P (LA) dosing in comparison with the conventional propranolol tablet (CP)."( Decreased absorption as a possible cause for the lower bioavailability of a sustained-release propranolol.
Kashiwada, K; Ogata, H; Ohira, M; Someya, K; Takahashi, H; Warabioka, R, 1990
)
0.28
" In our study linear dependence could be established only within a dosage range of 40 mg to 160 mg."( Dose-dependent bioavailability of propranolol.
Cvelbar, P; Francetić, I; Kopitar, Z; Lenardic, A; Vrhova, B; Zorz, M, 1986
)
0.27
" Propranolol decreased the migraine index more than 70% in 13 patients: five patients at a dosage of 40 mg/day, five patients at a dosage of 120 mg/day, and three patients at a dosage of 240 mg/day."( Propranolol plasma levels and relief of migraine. Relationship between plasma propranolol and 4-hydroxypropranolol concentrations and clinical effects.
Albani, F; Baldrati, A; Baruzzi, A; Cortelli, P; D'Alessandro, R; Lugaresi, E; Sacquegna, T, 1985
)
0.49
" Free propranolol concentrations were lower 7 and 11 hr after dosing in the MI group, but concentrations thereafter were of the same order as those in subjects with CP."( Propranolol disposition after acute myocardial infarction.
Norris, RM; Paxton, JW, 1984
)
0.27
" Following infusion of propranolol to the mother, steady-state plasma concentrations were obtained at three dosage levels in each of the eight animals studied."( The developing liver: the steady-state disposition of propranolol in pregnant sheep.
Hardy, KJ; Mihaly, GW; Morgan, DJ; Smallwood, R,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
naphtholsAny hydroxynaphthalene derivative that has a single hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Propranolol Pathway, Pharmacokinetics95

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Beta-1 adrenergic receptor Cavia porcellus (domestic guinea pig)Kd0.00580.00000.53588.3176AID42211
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (20)

Assay IDTitleYearJournalArticle
AID61088Compound was tested for its ability to block isoproterenol-induced increases in heart rate(HR) in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID61087Compound was tested for its ability to block isoproterenol-induced contractile force in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID42211Compound was evaluated for competitive antagonism of beta-1 adrenergic receptor in guinea pig atria measured as pA2 (-log KB)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.
AID1222752Unbound hepatobiliary clearance in human treated with propranolol2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID1137307Octanol-phosphate buffer partition coefficient, log P of the compound1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Relationship of nonspecific antiarrhythmic and negative inotropic activity with physicochemical parameters of propranolol analogues.
AID1137306Selectivity index, ratio of pED40 for tissue contractility to pED40 for maximum driving response in New Zealand White rabbit isolated atria1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Relationship of nonspecific antiarrhythmic and negative inotropic activity with physicochemical parameters of propranolol analogues.
AID58918Vasodilator potency relative to propranolol.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID41151Apparent pA2 value for blockade of isoproterenol-induced increase in heart rate evaluated against beta adrenergic receptor in anesthetized dogs1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis of 4'-hydroxypropranolol sulfate, a major non-beta-blocking propranolol metabolite in man.
AID1222754Fraction unbound in human treated with propranolol2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID40569Apparent pA2 value for isoproterenol-induced vasodilation (beta2) evaluated against beta-2 adrenergic receptor in anesthetized dogs1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis of 4'-hydroxypropranolol sulfate, a major non-beta-blocking propranolol metabolite in man.
AID1222755Systemic clearance in human treated with propranolol2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID42024Apparent pA2 value for myocardial contractile force (beta-1) evaluated against beta-1 adrenergic receptor in anesthetized dogs1985Journal of medicinal chemistry, Jun, Volume: 28, Issue:6
Synthesis of 4'-hydroxypropranolol sulfate, a major non-beta-blocking propranolol metabolite in man.
AID26292Partition coefficient (logD7.4)1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID1222753Unbound renal clearance in human treated with propranolol2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Which metabolites circulate?
AID41150Beta adrenergic receptor antagonist potency relative to propranolol.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID1137304Negative inotropic activity in New Zealand White rabbit isolated atria assessed as reduction of tissue contractility after 15 mins1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Relationship of nonspecific antiarrhythmic and negative inotropic activity with physicochemical parameters of propranolol analogues.
AID41482Compound was evaluated for competitive antagonism of beta-2 adrenergic receptor in rat uterus measured as pA2 (-log KB)1984Journal of medicinal chemistry, Jul, Volume: 27, Issue:7
The 3,4-catechol derivative of propranolol, a minor dihydroxylated metabolite.
AID58613Concentration required to decrease hindlimb perfusion pressure(55 mmHg) in anesthetized dogs after intra arterial administration.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID61089Compound was tested for its ability to block isoproterenol-induced vasodilation in anesthetized dogs.1981Journal of medicinal chemistry, Mar, Volume: 24, Issue:3
Ring-hydroxylated propranolol: synthesis and beta-receptor antagonist and vasodilating activities of the seven isomers.
AID1137302Antiarrhythmic activity in New Zealand White rabbit isolated atria assessed as reduction of maximum driving frequency after 15 mins1979Journal of medicinal chemistry, Jan, Volume: 22, Issue:1
Relationship of nonspecific antiarrhythmic and negative inotropic activity with physicochemical parameters of propranolol analogues.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (79)

TimeframeStudies, This Drug (%)All Drugs %
pre-199048 (60.76)18.7374
1990's19 (24.05)18.2507
2000's7 (8.86)29.6817
2010's4 (5.06)24.3611
2020's1 (1.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.27

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.27 (24.57)
Research Supply Index4.57 (2.92)
Research Growth Index4.26 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.27)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (5.49%)5.53%
Reviews1 (1.10%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other85 (93.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]